Methionine synthase (MS, also MTR) is a vitamin B12-dependent enzyme that catalyzes the remethylation of homocysteine to methionine using 5-methyltetrahydrofolate (5-MTHF) as the methyl donor. This reaction represents the rate-limiting step of the methionine cycle and serves as the critical junction connecting the folate cycle to cellular methylation pathways via SAMe production. The enzyme requires methylcobalamin (active B12) as a tightly bound cofactor and is the primary molecular target of B12 deficiency pathology.
Think of methionine synthase as a relay station where two parallel conveyor belts meet. On one belt, folate molecules arrive carrying methyl groups (5-MTHF). On the other belt, homocysteine molecules arrive needing those methyl groups to transform into methionine. The relay station worker is vitamin B12 in its methylcobalamin form—it's not just supervising, it's actively grabbing the methyl group from the folate belt, holding it briefly, then handing it to homocysteine on the other belt.
Without B12, the relay worker disappears. Now the folate belt backs up—all the folate gets stuck in the 5-MTHF form with nowhere to donate its methyl groups (the folate trap). Meanwhile, homocysteine piles up on the other belt, turning toxic. And downstream, the methionine belt runs empty, so there's no raw material to make SAMe, the universal methyl donor your body needs for hundreds of reactions—from neurotransmitter synthesis to DNA repair. This single broken relay station creates a three-way traffic jam: folate trapped, homocysteine toxic, methylation stalled.
Methionine synthase operates through a sophisticated three-step catalytic cycle centered on the cobalamin (B12) cofactor:
Step 1: Methyl Group Acceptance
- 5-MTHF donates its methyl group to the cobalt atom in cob(I)alamin (reduced B12)
- This produces tetrahydrofolate (THF, the recycled form) + methylcobalamin (methylB12)
- The methyl group is now bound to the cobalt center as Co-CH₃
Step 2: Methyl Group Transfer
- Homocysteine (containing a reactive thiol group) approaches the methylB12
- The methyl group transfers from cobalt to homocysteine's sulfur atom
- This regenerates methionine + cob(I)alamin (now in the "supernucleophile" reduced state)
Step 3: Enzyme Reactivation
- Every ~100-200 catalytic cycles, the cobalt center gets oxidized to inactive cob(II)alamin
- A reductive methylation reaction using SAMe and reductase enzymes restores the active methylB12 form
- This "rescue pathway" requires adequate SAMe levels, creating a feedback loop
graph TD
A[5-MTHF] -->|methyl donation| B[Methylcobalamin]
B -->|holds methyl group| C[Methyl-B12 intermediate]
C -->|methyl transfer| D[Homocysteine]
D -->|receives methyl| E[Methionine]
A -->|loses methyl| F[THF - recycled]
E -->|via MAT| G[SAMe]
G -->|methylation reactions| H[SAH]
H -->|SAH hydrolase| I[Homocysteine]
I -->|feeds back| D
B -->|occasional oxidation| J[Cob II alamin - inactive]
J -->|"SAMe + reductase"| B
K[Vitamin B12] -.->|cofactor| B
L[Zinc] -.->|cofactor support| B
Cofactor Requirements:
- Methylcobalamin (vitamin B12): absolutely required; cyanocobalamin must be converted to methylB12 first
- Zinc: supports enzyme structural integrity and catalytic efficiency
- SAMe: required for the periodic reactivation cycle (creates dependency loop)
Genetic Variants:
- MTR gene polymorphisms (e.g., A2756G) reduce enzyme activity 10-20%, increasing homocysteine and B12 requirements
- Combined with MTHFR variants, doubles homocysteine elevation risk
Methionine synthase dysfunction is the molecular bottleneck underlying B12 deficiency pathology and represents a perfect example of selfish brain theory—the brain prioritizes methylation-dependent neurotransmitter synthesis, so when methionine synthase fails, neurological symptoms often appear before hematological changes.
Clinical Presentations:
- Neurological: peripheral neuropathy, subacute combined degeneration of spinal cord, cognitive decline, depression (from depleted SAMe → impaired neurotransmitter synthesis)
- Hematological: megaloblastic anemia (from folate trap → impaired DNA synthesis)
- Cardiovascular: elevated homocysteine (>15 μmol/L) increases CVD risk 2-3x
- Psychiatric: depression, psychosis (especially in elderly with "functional B12 deficiency")
Evolutionary Mismatch Context:
Our ancestors consumed 5-10 μg/day of B12 from animal foods; modern vegans/vegetarians get <0.5 μg/day. The enzyme evolved assuming high-B12 availability. Proton pump inhibitors, metformin, and nitrous oxide further impair the system by blocking B12 absorption or inactivating the cobalt center.
Intervention Strategy:
- Target homocysteine: <7 μmol/L optimal (functional target), <10 μmol/L acceptable
- Methylcobalamin 1000-5000 μg: sublingual or intramuscular (bypass intrinsic factor pathway)
- Avoid cyanocobalamin: requires conversion via limited reductase enzymes
- Co-supplementation: 5-MTHF (400-800 μg), zinc (15-30 mg), vitamin B6 (25-50 mg as cofactor for downstream transsulfuration)
- Address root causes: PPI cessation, treat atrophic gastritis, screen for pernicious anemia (anti-intrinsic factor antibodies)
Metamodel Connections:
- Metamodel 0 (Genetics): MTR polymorphisms increase vulnerability
- Metamodel 1 (Lifestyle): vegan diets, alcohol consumption impair enzyme function
- Metamodel 2 (Chronic inflammation): inflammatory cytokines downregulate methionine synthase expression
- Metamodel 5 (Evolutionary mismatch): modern processed diets + medication use vs. ancestral B12-rich intake
Exam-Relevant Clinical Vignette:
A 65-year-old vegetarian presents with depression, fatigue, and paresthesias. Homocysteine 22 μmol/L, MCV 105 fL, B12 borderline at 250 pmol/L. This is classic methionine synthase dysfunction from dietary B12 insufficiency. First-line: methylcobalamin 5000 μg sublingual daily + 5-MTHF 800 μg. Recheck homocysteine in 8 weeks (target <10).
- Methionine synthase is the only enzyme that recycles 5-MTHF back to THF, making it the escape valve from the folate trap
- Requires methylcobalamin (not cyanocobalamin, hydroxocobalamin, or adenosylcobalamin)
- Catalytic efficiency decreases 40-60% with B12 levels <300 pmol/L (even if technically "normal")
- Every 100-200 cycles, the cobalt center oxidizes and requires SAMe-dependent reactivation (creating a catch-22 in deficiency)
- MTR A2756G polymorphism present in 15-20% of populations; reduces activity and increases homocysteine by 1-2 μmol/L
- Target homocysteine: <7 μmol/L optimal for cardiovascular/cognitive health; >15 μmol/L indicates severe dysfunction
- Zinc deficiency impairs enzyme function independent of B12 status; optimal zinc: 12-16 μmol/L serum
- Nitrous oxide (surgical anesthesia, recreational use) irreversibly inactivates the cobalt center; single exposure can cause acute neurological crisis
- Metformin reduces B12 absorption 10-30% via calcium-dependent ileal uptake mechanism; 10-25% of long-term users develop deficiency
- Intervention dosing: methylcobalamin 1000-5000 μg sublingual daily (doses >1000 μg saturate passive absorption); severe cases require 1000 μg IM weekly x 6 weeks
- Co-supplementation with 5-MTHF (400-800 μg) bypasses MTHFR bottleneck and provides immediate methyl donor
- vitamin B12 — methylcobalamin form is the essential bound cofactor required for every catalytic cycle
- methylcobalamin — active B12 form that directly participates in methyl transfer; cyanocobalamin must be converted first
- 5-MTHF — methyl donor substrate; enzyme converts 5-MTHF back to THF, preventing folate trap
- homocysteine — substrate converted to methionine; accumulates when enzyme is deficient (neurotoxic, atherogenic)
- methionine — product of the reaction; depleted in B12 deficiency leading to SAMe shortage
- SAMe — downstream product (methionine → SAMe via MAT); required for 200+ methylation reactions including neurotransmitter synthesis
- folate cycle — methionine synthase is the critical junction linking folate recycling to methylation pathways
- methylation cycle — this enzyme is the rate-limiting step; impairment stalls all methylation-dependent processes
- folate trap — when enzyme fails, all cellular folate accumulates as 5-MTHF with no escape route
- B12 deficiency — primary cause of enzyme dysfunction; explains multi-system pathology (neuro, heme, cardio)
- megaloblastic anemia — result of folate trap → impaired thymidylate synthesis → ineffective erythropoiesis
- depression — SAMe depletion impairs synthesis of serotonin, dopamine, norepinephrine
- cardiovascular disease — homocysteine >15 μmol/L increases CVD risk through endothelial damage and oxidative stress
- zinc — cofactor supporting enzyme structure and activity; deficiency impairs function independent of B12
- MTHFR — upstream enzyme producing 5-MTHF substrate; combined MTHFR + MTR variants synergistically elevate homocysteine
- choline — alternative methyl donor pathway (choline → betaine → methionine via BHMT) bypasses methionine synthase
- BHMT — alternative remethylation enzyme using betaine; doesn't require B12 but only active in liver/kidney
- acetylcholine — synthesis requires choline-methionine interconversion; impaired when methionine synthase fails
- DNA methylation — SAMe-dependent process; methionine synthase dysfunction reduces global methylation affecting gene expression
- Alzheimer's Disease — elevated homocysteine (>14 μmol/L) increases risk 2x; proposed mechanism includes SAMe depletion and vascular damage
- chronic inflammation — inflammatory cytokines (TNF-α, IL-1β) downregulate methionine synthase expression via NF-κB signaling
- cognitive decline — B12 deficiency and elevated homocysteine accelerate brain atrophy 5-10x in elderly
- peripheral neuropathy — demyelination from impaired methylation of myelin basic protein
- metformin — reduces B12 absorption; 10-25% of long-term users develop functional B12 deficiency requiring monitoring
- proton pump inhibitors — impair B12 absorption by reducing gastric acid needed to cleave B12 from food proteins